Ookawara, Mitsugi et al
"The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight." Journal of Pharmacology and Experimental Therapeutics
375.1
(2020):
21-27.
Web. 21 Oct. 2020.
